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Abstract
Background: The NG2 proteoglycan is expressed by several cell types in demyelinated lesions and has important
effects on the biology of these cells. Here we determine the cell-type-specific roles of NG2 in the oligodendrocyte
progenitor cell (OPC) and myeloid cell contributions to demyelination and remyelination.
Methods: We have used Cre-Lox technology to dissect the cell-type-specific contributions of NG2 to myelin damage
and repair. Demyelination is induced by microinjection of 1 % lysolecithin into the spinal cord white matter of control,
OPC-specific NG2-null (OPC-NG2ko), and myeloid-specific NG2-null (My-NG2ko) mice. The status of OPCs, myeloid cells,
axons, and myelin is assessed by light, immunofluorescence, confocal, and electron microscopy.
Results: In OPC-NG2ko mice 1 week after lysolecithin injection, the OPC mitotic index is reduced by 40 %, resulting in
25 % fewer OPCs at 1 week and a 28 % decrease in mature oligodendrocytes at 6 weeks post-injury. The initial
demyelinated lesion size is not affected in OPC-NG2ko mice, but lesion repair is delayed by reduced production of
oligodendrocytes. In contrast, both the initial extent of demyelination and the kinetics of lesion repair are
decreased in My-NG2ko mice. Surprisingly, the OPC mitotic index at 1 week post-injury is also reduced (by 48 %)
in My-NG2ko mice, leading to a 35 % decrease in OPCs at 1 week and a subsequent 34 % reduction in mature
oligodendrocytes at 6 weeks post-injury. Clearance of myelin debris is also reduced by 40 % in My-NG2ko mice.
Deficits in myelination detected by immunostaining for myelin basic protein are confirmed by toluidine blue
staining and by electron microscopy. In addition to reduced myelin repair, fewer axons are found in 6-week
lesions in both OPC-NG2ko and My-NG2ko mice, emphasizing the importance of myelination for neuron survival.
Conclusions: Reduced generation of OPCs and oligodendrocytes in OPC-NG2ko mice correlates with reduced
myelin repair. Diminished demyelination in My-NG2ko mice may stem from a reduction (approximately 70 %) in
myeloid cell recruitment to lesions. Reduced macrophage/microglia numbers may then result in decreased
myelin repair via diminished clearance of myelin debris and reduced stimulatory effects on OPCs.
Keywords: Demyelination, Remyelination, Oligodendrocyte progenitors, Macrophages/microglia, Axon loss, NG2,
CSPG4, Conditional knockout mice
Background
Damage to the myelin sheath not only impairs impulse
transmission in central nervous system (CNS) axons but
also leads to eventual loss of the neurons themselves [1, 2].
New oligodendrocytes for myelin repair are generated by
so-called adult oligodendrocyte progenitor cells (OPCs)
[3, 4] that represent the largest cycling population in
the mature CNS [5–8]. Adult OPCs are effective in
generating myelinating oligodendrocytes to repair
lesions in experimental demyelination models and in
the early stages of demyelinating pathologies. However,
remyelination in chronic stages of multiple sclerosis
(MS) is less impressive [9, 10], partly due to several
factors in addition to OPCs and neurons that contribute
to the disease process. For example, macrophages and
microglia are key participants in the initial stages of
myelin damage but are also required for the removal of
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myelin debris necessary to allow effective repair. Myeloid
cells also produce factors that promote recruitment, prolif-
eration, and differentiation of OPCs [11–13]. A more
complete understanding of MS therefore requires delinea-
tion of the respective contributions of these various cell
types to the disease process.
We have identified the NG2 proteoglycan, also known as
chondroitin sulfate proteoglycan 4 (CSPG4), as a factor
that influences developmental myelination and is also in-
volved in both myelin damage and repair. During develop-
ment, NG2 is required for effective expansion of the OPC
pool. In germline NG2-null mice, reduced numbers of
OPCs result in generation of reduced numbers of myelina-
ting oligodendrocytes and to delayed myelination [14]. In a
pathological model involving lysolecithin microinjection
into the spinal cords of germline NG2-null mice, the extent
of demyelination is reduced compared to demyelination
seen in wild-type mice [15]. Nevertheless, myelin repair is
also retarded in germline NG2-null mice. The complexity
of these effects of NG2 ablation may be partly due to NG2
effects on three distinct populations of cells during demye-
lination and remyelination. NG2 is expressed by OPCs,
macrophages/microglial cells, and microvascular pericytes
associated with lysolecithin-induced lesions in the mouse
spinal cord. Germline ablation of NG2 leads to reduced
numbers of all three cell types in these lysolecithin-
induced lesions [15], suggesting a role for NG2 in recruit-
ment and/or expansion of these populations. In contrast,
use of an experimental autoimmune encephalomyelitis
(EAE) model has failed to detect NG2-dependent contri-
butions of OPCs and myeloid cells to myelin damage and
repair [16]. It is therefore important to more carefully
analyze and dissect the roles of NG2 in the respective con-
tributions of these cell populations to the demyelination/
remyelination process.
In this report, we describe a Cre-Lox approach that
generates OPC-specific NG2-null (OPC-NG2ko) and
myeloid-specific NG2-null (My-NG2ko) mice. We show
that, following lysolecithin-induced spinal cord demyelin-
ation, OPC-specific NG2 ablation negatively affects only
the process of myelin repair, while myeloid-specific NG2
ablation reduces both myelin damage and repair. Our
results begin to characterize the NG2-dependent changes
in OPCs and myeloid cells that underlie the contrasting
phenotypes of the OPC-NG2ko and My-NG2ko mice.
Methods
Animals
Animal work was performed in the AAALAC-accredited
vivarium of the Sanford Burnham Prebys (SBP) Medical
Discovery Institute according to guidelines approved by
the Office of Laboratory Animal Welfare. All experimen-
tal protocols were approved by the SBP Institutional
Animal Care and Use Committee. In order to generate
cell-type-specific NG2-null animals, mice carrying loxP-
flanked (“floxed”; fl) NG2 alleles were crossed with mice
expressing Cre from the oligodendrocyte transcription
factor 2 (Olig2) locus (Olig2Cre) or with lysozyme M-Cre
(LysMCre) mice. The experiments reported here utilize
male control (NG2fl/fl), OPC-NG2ko (NG2fl/fl/Olig2Cre),
and My-NG2ko (NG2fl/fl/LysMCre) mice between the
ages of 3 and 5 months. Mice with specific ablation of
NG2 in OPCs were generated by crossing NG2 floxed
mice [17, 18] with Olig2-Cre transgenic mice [19]. Olig2
is expressed in cells of the oligodendrocyte lineage, in
motor neuron precursors, and in some radial glia. Since
NG2 is expressed by OPCs, but not by motor neuron
precursors or radial glia, the Olig2Cre mouse is well-
suited for ablating NG2 specifically in OPCs. Mice with
myeloid-specific ablation of NG2 were generated by
crossing NG2 floxed mice with LysMCre transgenic mice
[20, 21], a well-established Cre driver line for gene abla-
tion in myeloid cells.
Lysolecithin-induced spinal cord demyelination
Spinal cord demyelination was carried out as previously
described [15], using male mice (25–40 g) anesthetized
with ketamine/xylazine (100/10 mg/kg) administered
intraperitoneally. A 1.5-μl solution of 1 % lysophosphati-
dylcholine (L-α-lysolecithin; Sigma, St. Louis, MO) in
0.1 M phosphate buffered saline (PBS) was injected at a
rate of 0.5 μl/min into the white matter between the
Th12 and Th13 vertebrae, just lateral to the posterior
spinal vein, at depths of 0.8 and 0.4 mm (1.5 min at each
depth). The needle was left in place for an additional
2 min to avoid backflow. Sham-operated controls con-
sisted of identical injections with 0.1 M PBS, followed by
euthanasia at 7 days post-surgery. Some animals received
intraperitoneal doses of 5-bromo-2-deoxyuridine (BrdU,
80 mg/kg) on post-surgery day 4, 3 days prior to euthan-
asia at day 7. For final analyses, animals were deeply anes-
thetized with ketamine/xylazine (100/10 mg/kg) and
transcardially perfused with 0.1 M PBS, followed by 4 %
paraformaldehyde (pH 7.4).
Tissue preparation and immunocytochemistry
Spinal cords were removed after transcardial perfusion
with 0.1 M phosphate buffer containing 4 % paraformalde-
hyde (pH 7.4). Tissue was post-fixed for 24 h at 4 °C and
then cryoprotected for 24 h at 4 °C in 0.1 M phosphate
buffer containing 20 % sucrose. Transverse sections
(30 μm) were cut at −16 °C on a cryostat microtome
(Cryocut, 1800) and collected free-floating in 0.1 M PBS
containing 0.02 % sodium azide. For immunostaining, free-
floating sections were first incubated for 60 min at room
temperature in 0.1 M PBS containing 5 % normal donkey
serum and 0.5 % Triton X-100. Sections were then incu-
bated overnight at 4 °C with primary antibodies diluted in
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PBS containing 0.8 % Triton X-100, 0.02 % sodium azide,
and 5 % normal donkey serum. In order to perform double
or triple immunolabeling, respective primary and second-
ary antibody combinations were used sequentially. The fol-
lowing primary antibodies were used: (1) guinea pig or
rabbit anti-NG2 (1:50 or 1:200) [22]; (2) rabbit or rat anti-
platelet-derived growth factor receptor alpha (PDGFRα,
[23] or eBioscience, 1:200); (3) mouse, rat, or rabbit anti-
myelin basic protein (MBP, Sternberger MSMI 94, Invitro-
gene or Origene, 1:500); (4) rat anti-cluster of differenti-
ation 18, integrin beta-2 (CD18; eBioscience, 1:200); (5)
rabbit or goat anti-IBA1 (Wako, 1:1000, or Abcam, 1:500);
(6) rat anti-F4/80 (Invitrogen, 1:100); (7) rat anti-BrdU
(OBT0030G, Serotec, 1:50); (8) mouse anti-pan-axonal
neurofilament (smi-312R, Sternberger, 1:1000); (9) rabbit
anti-Olig2 (Abcam or PhosphoSolutions, 1:200); and (10)
mouse anti-adenomatous polyposis coli (APC; clone CC1,
Calbiochem, 1:50). After three 10-min washes with PBS,
the sections were incubated with appropriate combina-
tions of highly cross-adsorbed donkey secondary anti-
bodies conjugated to Alexa488, CY3, and/or Alexa 647
(Jackson ImmunoResearch). Secondary antibodies were
diluted 1:250 in the same solution as the primary antisera.
For BrdU immunolabeling, sections were incubated in 2N
HCl for 30 min at 37 °C, followed by boric acid
neutralization (pH 8.5) for 10 min, and then processed via
the immunostaining protocol described above. 4′-6-diami-
dino-2-phenylindole (DAPI, 4 μg/mL, D3571, Invitrogen)
was used for general nuclear staining of all sections. After
washing three times for 10 min with PBS, sections were
mounted on slides, air-dried, and then cover-slipped with
Vectashield (H-1000, Vector lab).
Electron microscopy
Animals were transcardially perfused with 2.5 % glutaral-
dehyde plus 2 % paraformaldehyde in 0.1 M cacodylate
(EM grade from Electron Microscopy Science) buffer
(pH 7.4). Spinal cords were post-fixed with 1 % osmium
tetroxide and embedded in Durcupan or Embed 812.
Semi-thin (0.5 μm) and ultra-thin (60 nm) sections were
prepared using Reichert-Jung ultramicrotomes. Toluidine-
blue-stained semi-thin sections were examined by light
microscopy (BX51 Olympus microscope equipped with an
Optronics Microfire digital camera). Ultra-thin sections
were examined by transmission electron microscopy using
an FEI Technai Spirit G2 BioTWIN microscope equipped
with a bottom mount Eagle 4k (16 megapixel) camera.
Preparation of myelin
Crude myelin fractions from wild-type mouse brains
were isolated by classical sucrose gradient centrifugation
protocols [24]. In brief, brains were homogenized in
0.3 M sucrose and protease inhibitors. The homogenate
was layered over 0.83 M sucrose and ultracentrifuged for
30 min at 75,000×g at 4 °C. Crude myelin was collected
from the 0.3:0.8 M sucrose interface, resuspended in
20 mM Tris·Cl buffer (pH 7.45), and further purified by
additional ultracentrifugation and two cycles of hypoos-
motic shock.
Bone marrow transplantation and preparation of bone-
marrow-derived macrophages for phagocytosis assays
Wild-type and germline NG2-null mice on a β-actin-
EGFP (enhanced green fluorescent protein) background
were used as donors for bone marrow (BM) transplant-
ation, as previously described [25, 26]. Gamma-
irradiated wild-type and germline NG2-null mice served
as recipients for EGFP-positive wild-type and germline
NG2-null bone marrow, respectively. Bone marrow was
harvested from euthanized wild-type and germline NG2-
null β-actin-EGFP donor mice. Dissected femurs and tib-
iae were flushed with sterile 0.1 M PBS containing 5 mM
EDTA and 2 % FCS, and red blood cells were lysed by an
addition of two volumes of ACK buffer. Surviving BM
cells were washed, filtered through a nylon mesh, and
resuspended in sterile 0.1 M PBS containing 2 % mouse
serum. Recipient mice each received 700,000 cells via
retro-orbital injection. After a 6-week recovery, chimeric
mice with at least 75 % engraftment were used for lysolec-
ithin injection into the spinal cord. Infiltration of EGFP-
positive cells into demyelinated lesions was assessed
1 week after lysolecithin injection.
For preparation of bone-marrow-derived macrophages,
wild-type and germline NG2-null mice were euthanized
by CO2 asphyxia, and BM cells were harvested as de-
scribed above for BM transplantation. Following previ-
ously published protocols [25, 27], washed BM cells were
adjusted to a density of 106 cells/mL and cultured for
3 days in 10 % CO2 in a basic medium containing 1 nM
IL-3 and 0.22 nM M-CSF (R&D and Peprotech, respect-
ively). Non-adherent cells were collected, seeded at 6000
cells per well in 384 well tissue-culture plates (781901;
Greiner Bio-one), and incubated in a basic medium with
0.44 nM M-CSF for four additional days. After washing
with PBS, myeloid cells were incubated for 16 h in a
serum-free macrophage medium (12065-074, Gibco).
Phagocytic assays were performed on the following day by
addition of 0.5 μg of crude myelin to each well. After 2, 4,
6, and 8 h of incubation, wells were washed, and cells were
fixed with 4 % paraformaldehyde. Phagocytized myelin
was quantified by double immunolabeling with MBP and
CD18 antibodies.
Image processing and quantification
At least four control, four OPC-NG2ko, and four My-
NG2ko mice were examined for various aspects of demye-
lination and remyelination at each time point. Quantita-
tive analysis of myelin and myelin debris in ventral and
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dorsal columns was performed in five transverse sections
separated by intervals of 600 μm, thus spanning a distance
of 2400 μm along the spinal cord (1200 μm on either side
of the lesion). Comparison of MBP-positive volumes in
the spinal cord did not reveal significant differences
between non-operated and sham-operated animals, estab-
lishing that the sham operation did not affect the status of
myelin. Sham-operated mice injected with 1.5 μL of 0.1 M
PBS and surviving for 1 week were therefore used as con-
trols for comparisons with all other lysolecithin-injected
mice. Sections double-stained with antibodies against
MBP and CD18 (or in some cases CD11b, F4/80, or ion-
ized calcium binding adaptor molecule 1 (Iba1)) were
scanned via confocal microscopy (LSM 710 NLO Zeiss;
ZEN 2010), and colocalization of MBP-positive myelin
debris in CD18-positive myeloid cells was evaluated using
Image-Pro Plus 5.1 (Media Cybernetics). In order to quan-
tify non-phagocytized MBP (i.e., intact myelin), phagocy-
tized MBP pixels associated with CD18-positive cells were
subtracted from total MBP pixels. Based on multiple ob-
servations, the intensity threshold representing positively
labeled areas was chosen approximately 30 % above the
background color. The average MBP-positive volume in
sham-operated control Cre-negative mice was designated
as 100 % and was used for comparison with MBP-positive
volumes in all other experimental mice microinjected with
either PBS or lysolecithin.
In order to compare axon number and the extent of
axon myelination in control, OPC-NG2ko, and My-NG2ko
mice 6 weeks after lysolecithin microinjection, three sec-
tions separated by intervals of 600 μm (thus spanning a
distance of 1800 μm along the spinal cord) were double-
labeled with pan-neurofilament (NF) and MBP antibodies.
Axon abundance, axon diameter, and the extent of MBP-
NF association were quantified by confocal microscopy in
1-μm optical sections using Image-Pro Plus software.
Identification of OPCs in lysolecithin-injected mice was
complicated by our finding that PDGFRα was expressed
not only by Olig2-positive OPCs but also by a population
of Olig2-negative cells that appeared to arise from the
meninges, as we have previously noted in spinal cord
injury studies [23]. These Olig2-negative cells also con-
tinued to express NG2 in OPC-NG2ko mice, further
distinguishing them from OPCs. While we suspect that
these PDGFRα-positive non-OPCs may also contribute
to the demyelination/remyelination phenotype, we did
not wish to consider their impact in the current studies.
We therefore eliminated these cells from our analyses
by using double immunolabeling for PDGFRα and
Olig2 to definitively identify OPCs.
OPC and myeloid cell proliferation was evaluated in
sections immunostained for PDGFRα, Olig2, IBA1, and
BrdU. Since PDGFRα and Olig2 are expressed on the cell
surface and in nuclei, respectively, they were visualized
using the same primary and secondary antibodies, while
BrdU was visualized with a different primary-secondary
antibody combination. In control, OPC-NG2ko, and My-
NG2ko mice, mitotic indices for PDGFRα+/Olig2+ and
IBA1+ cells were calculated by determining the percentage
of cells in each of these two populations that were labeled
for BrdU in single optical sections.
Statistical analysis
Data were analyzed for statistical significance using un-
paired t-tests and ANOVA. P values less than 0.05 were
considered statistically significant.
Results
Cell-type-specific ablation of NG2
Previously, we found that germline ablation of NG2 af-
fected the behavior of three different cell types during
spinal cord demyelination and remyelination. Recruitment
and abundance of oligodendrocyte progenitors (OPCs),
pericytes, and macrophages/microglia were all diminished
in germline NG2-null mice [15]. By using Cre-Lox-
mediated ablation of NG2 in OPCs and in myeloid cells,
our current study seeks to dissect the specific roles of
NG2 in these two key cell types. For specific ablations of
NG2 in OPCs (OPC-NG2ko) and in myeloid cells (My-
NG2ko), NG2 floxed mice [17, 18] were crossed with
Olig2Cre [19] and LysMCre [20, 21] mice, respectively.
Our previous demonstration of OPC-specific NG2 abla-
tion in the hypothalamus of OPC-NG2ko mice [17] is
confirmed here by immunolabeling for NG2 and OPC-
specific markers (PDGFRα and Olig2) in sham-operated
and lysolecithin-injected spinal cords. Quantitative three-
dimensional analysis of immunolabeled specimens from
control (Fig. 1a–d), OPC-NG2ko (Fig. 1e–h), and My-
NG2ko (Fig. 1i–l) mice indicates that the efficiency of
NG2 ablation in PDGFRα+/Olig2+ cells in three OPC-
NG2ko mice is 92, 95, and 98 %, respectively (average
95 %), whereas pericyte and myeloid cell expression of
NG2 is not affected in these mice. In contrast, OPC
expression of NG2 is unaffected in My-NG2ko mice.
Myeloid-specific NG2 ablation in these mice, previously
reported in the case of brain tumors [28], is confirmed
here (Fig. 1) by comparisons of sham-operated and
lysolecithin-injected spinal cords from control, OPC-
NG2ko, and My-NG2ko mice via immunolabeling for
NG2 and the myeloid markers CD18, CD11b, and F4/80,
respectively. The analysis of NG2 ablation in myeloid cells
is complicated by the fact that NG2 is not expressed by
100 % of any of these three myeloid populations in the
lesions in control mice. In these controls, NG2 is found
on 60 % of CD18-positive cells, 40 % of CD11b-positive
cells, and 45 % of F4/80-positive cells. This may be due to
the inherent heterogeneity of myeloid populations or be-
cause NG2 is expressed only transiently by myeloid cells
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(or both). Nevertheless, in lesions in My-NG2ko mice,
NG2 expression is present on only 25 % of CD18-positive
macrophages (Fig. 1l). Similar myeloid-specific absence of
NG2 expression was noted using CD11b (18 % NG2-
positive) or F4/80 (12 % NG2-positive) as myeloid cell
markers (results not shown). A further complication is the
likelihood of at least some phagocytosis of shed NG2 by
myeloid cells. Since phagocytosed NG2 is difficult to
distinguish clearly from cell surface NG2 on the basis of
immunoreactivity, this might result in under-estimation
Fig. 1 Cell-type-specific ablation of NG2. a, b Sham-operated control mice: b NG2 (blue) and PDGFRα (Pα, green) are both expressed by OPCs
(arrowhead) in control mice injected with PBS (Sham-Cont). a To emphasize the presence or absence of NG2, NG2 alone is shown in white in the same
field as b. e, f Sham-operated OPC-NG2ko mice: f NG2 (blue) is not detected in PDGFRα-positive OPCs (arrows, green) in OPC-specific NG2-null mice
(O-cKO). e Same field as (f), NG2 alone (white). In both control and OPC-NG2ko genotypes, NG2 is expressed by pericytes observed in close proximity to
CD31-positive endothelial cells (red; (b, f)). i, j Sham-operated My-NG2ko mice: j NG2 (blue) is expressed by Pα-positive OPCs (green, arrowhead)
but is absent from IBA1-positive myeloid cells (red, asterisk) in myeloid-specific NG2-null mice (M-cKO). i Same field as (j), NG2 alone (white).
c, d Lysolecithin-injected control mice at 1 week post-injury: d In demyelinated lesions in control mice 1 week after lysolecithin injection (Cont-1W), NG2
(blue) is expressed by Pα-positive OPCs (green, arrowheads) and by CD18-positive macrophages/microglial cells (red, double arrowheads). c Same field as
(f), NG2 alone (white). g, h Lysolecithin-injected OPC-NG2ko mice at 1 week post-injury. h In demyelinated lesions in OPC-specific NG2-null mice 1 week
after lysolecithin injection (O-cKO-1W), NG2 (blue) is ablated in Pα-positive OPCs (green, arrows) but is still expressed by CD18-positive myeloid cells
(red, double arrowheads). g Same field as (h), NG2 alone (white). Compared to sham-operated animals, OPCs and myeloid cells are more abundant in
demyelinated lesions. k, l Lysolecithin-injected My-NG2ko mice at 1 week post-injury: l In demyelinated lesions in myeloid-specific NG2-null mice 1 week
after lysolecithin injection (M-cKO-1W), NG2 (blue) is expressed by Pα-positive OPCs (green, arrowheads) but is absent from CD18-positive myeloid cells
(red, asterisks). k Same field as (l), NG2 alone (white). Scale bar is 20 μm
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of NG2 ablation in myeloid cells. In light of these un-
certainties, the most conservative statement to be made is
that NG2 is present on only 25 % of CD18-positive mye-
loid cells in My-NG2ko mice, compared to 60 % of CD18-
positive cells in control mice. The significance of this re-
duction is supported by the resulting robust effect on
myeloid cell recruitment in My-NG2ko mice.
Kinetics of myelin damage and repair
Quantitative assessment of MBP-positive volumes in the
spinal cords of sham-operated animals (Fig. 2e (Sham))
reveals very similar levels of overall myelination in con-
trol, OPC-NG2ko, and My-NG2ko mice. This is import-
ant for establishing that levels of myelination in the two
lines of cell-type-specific NG2-null mice are not defi-
cient prior to lysolecithin microinjection. One week after
lysolecithin injection, the volume of the demyelinated
lesion in OPC-NG2ko mice (Fig. 2c) does not differ
significantly from the lesion volume seen in control mice
(Fig. 2b). In contrast, the initial extent of myelin damage
at 1 week in My-NG2ko mice (Fig. 2d) is significantly re-
duced compared to that seen in controls. These MBP
volumes are quantified in Fig. 2e (1W). Figure 2e also
shows that at 2 weeks post-injection, the initiation of
lesion repair is evident in control mice (2W) and con-
tinues to improve at 6 weeks (6W). In contrast, lesion
repair has not yet begun in OPC-NG2ko and My-
NG2ko mice at 2 weeks and still lags behind repair in
control mice at 6 weeks. In summary, myelin damage is
reduced only in My-NG2ko mice, while myelin repair is
diminished by cell-type-specific ablation of NG2 in both
OPCs and myeloid cells.
Macrophage recruitment and phagocytic function
Macrophage recruitment to lesions was evaluated 1 week
after lysolecithin injection by immunolableling for CD18
(integrin subunit β2). The abundance of CD18-positive
cells and the corresponding volume of infiltration in My-
NG2ko mice (Fig. 2f) are greatly reduced compared to the
values seen in control mice. In contrast, macrophage re-
cruitment is not significantly altered in OPC-NG2ko mice.
Similar results were obtained using CD11b (integrin sub-
unit αM), F4/80, or Iba1 as macrophage markers, showing
that the determination of myeloid cell abundance is inde-
pendent of the choice of marker. Cell proliferation may
also play a role in this distinction between control and
My-NG2ko mice. As judged by BrdU incorporation, the
mitotic index of IBA1-positive cells is reduced by 44 % in
lesions in My-NG2ko mice, compared to control mice.
A similar reduction in macrophage recruitment to le-
sions is seen at 1 week post-injury in EGFP bone-marrow-
transplanted mice. Compared to wild-type mice receiving
EGFP-labeled bone marrow from wild-type donors, NG2-
null mice receiving EGFP-labeled bone marrow from
germline NG2-null donors exhibit a greatly reduced influx
of EGFP-positive cells expressing the F4/80 macrophage
marker (Fig. 2g–j). Moreover, the fact that F4/80-positive/
EGFP-positive cells outnumber F4/80-positive/EGFP-nega-
tive cells by a ratio of 8:1 in WT-to-WT chimeric mice
demonstrates that bone-marrow-derived macrophages, ra-
ther than resident microglia, comprise the majority of mye-
loid cells recruited to these lesions (Fig. 2g, i). By contrast,
this macrophage:microglia ratio falls to 1:3 in KO-to-KO
chimeric mice, reflecting the large decrease in macrophage
recruitment to these lesions. These findings of reduced
macrophage recruitment mirror the differences in demye-
lination observed via MBP labeling in Fig. 2e, suggesting a
strong correlation between macrophage abundance and
lesion severity. Data for macrophage recruitment are sum-
marized in Table 1, row 3.
In addition to being responsible for the initial damage to
myelin, a contrasting function of macrophages required
for lesion repair is the phagocytic clearance of myelin deb-
ris. By double labeling for MBP and CD18, we were able
to quantify phagocytized myelin within myeloid cells at
1 week post-injury (Fig. 3j, k). At this time point, overall
phagocytosis of myelin is reduced by 40 % in My-NG2ko
mice compared to controls (Fig. 3k). The fact that this dif-
ference is not seen when analyzed at the level of individual
macrophages (Fig. 3j) could indicate that the overall
difference in phagocytosis is based solely on reduced
macrophage abundance in My-NG2ko mice. However, we
have been able to detect a difference in phagocytic cap-
ability via in vitro comparisons of control and NG2-null
bone-marrow-derived macrophages (Fig. 3a–i). Compared
to controls, NG2-null macrophages appear deficient in
their ability to phagocytize myelin when quantified on an
MBP/cell basis. The fact that phagocytosis by control
macrophages does not continue to increase after 4 h may
indicate that macrophage capacity is saturated at this
point, offering a possible explanation for the lack of a dif-
ference in MBP phagocytosis per cell in vivo; that is, after
1 week, NG2 macrophages may have had ample time to
catch up with their wild-type counterparts.
OPC abundance and proliferation in OPC-NG2ko and
My-NG2ko mice
In the spinal cords of untreated adult OPC-NG2ko mice,
there are small, statistically insignificant decreases in the
number of OPCs and total number of Olig2-positive cells,
compared to control mice (Table 1, rows 1 and 2). My-
NG2ko mice are indistinguishable from control mice in
this regard. Along with the indistinguishable MBP-positive
volumes shown in Fig. 2e, these data are important for
establishing that, prior to lysolecithin injection, all three
mouse lines are very similar in terms of oligodendrocyte
lineage cell populations and overall levels of myelination.
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Fig. 2 (See legend on next page.)
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One week after lysolecithin injection, reduced OPC dens-
ity is seen in lesions in OPC-NG2ko mice (Fig. 4b, e, h),
compared to lesions in control mice (Fig. 4a, d, g). Some-
what surprisingly, OPC density is also reduced to a similar
or even greater extent in lesions in My-NG2ko mice (Fig. 4c,
f, i). These data are quantified in Table 1, row 4. In order to
determine whether decreased OPC numbers are due to re-
duced OPC proliferation, we quantified BrdU incorporation
into Pα+/Olig2+ cells at the 1-week time point. Interestingly,
numbers of BrdU-positive OPCs are reduced in lesions in
both OPC-NG2ko (Fig. 5b, e) and My-NG2ko (Fig. 5c, f)
mice compared to lesions in control mice (Fig. 5a, d).
Mitotic indices for OPCs are quantified in Table 1, row 5.
Oligodendrocyte abundance and axon myelination in
OPC-NG2ko and My-NG2ko mice
Reduced abundance of OPCs due to decreased proliferation
might result in smaller numbers of mature oligodendro-
cytes available for myelin repair. We used immunolabeling
for APC to assess numbers of mature oligodendrocytes at
6 weeks post-injury. Figure 6b, c reveal a reduction in oligo-
dendrocyte density in both OPC-NG2ko and My-NG2ko
mice, respectively, compared to controls (Fig. 6a). These
results are quantified in Table 1, row 6.
A more detailed picture of axon remyelination at 6 weeks
post-injury was obtained via double immunolabeling for
MBP and NF, followed by quantification of the association
Table 1 Effects of cell-type-specific ablation of NG2 on cell and axon biology
Row Control OPC-NG2ko My-NG2ko
Sham-operated animals
1 Number of Olig2+ cells 115.27 ± 3.8 111.02 ± 5.7 117.63 ± 5.4
2 Number of Olig2+/PDGF-Rα+ OPCs 14.55 ± 1.7 12.31 ± 2 14.46 ± 3.5
1 week after demyelination
3 Number of Iba1+ macrophages/microglia 117.19 ± 22.3 120.1 ± 28.1 39.64 ± 19.8**
4 Number of Olig2+/PDGF-Rα+ OPCs 42.92 ± 1.5 32.4 ± 1.7*** 23.02 ± 7.2***
5 Mitotic index of Olig2+/PDGF-Rα+ OPCs (%) 22.91 ± 3.5 13.49 ± 1.5** 11.93 ± 2.1***
6 weeks after demyelination
6 Number of APC+ oligodendrocytes 62.14 ± 6.7 44.48 ± 8.6* 43.17 ± 4.1**
7 Well-myelinated axons 1056 ± 133 480 ± 128** 499 ± 80**
8 Myelin thickness (g value) 0.745 ± 0.089 0.861 ± 0.099*** 0.87 ± 0.065***
9 Number of NF-positive axons
Small: diameter < 1 μm 1103 ± 60 660 ± 66*** 812 ± 85**
Medium: diameter = 1–2.5 μm 201 ± 29 135 ± 10* 118 ± 14*
Large: diameter > 2.5 μm 18 ± 3 6 ± 1** 8 ± 2*
The key parameters for Olig2/PDGFRα-positive OPCs, Iba1-positive macrophages/microglia, and APC-positive oligodendrocytes were quantified in lesions in control,
OPC-NG2ko, and My-NG2ko mice (n = 4 for each group) from 1 to 6 weeks after lysolecithin injection. The rationale for using Iba1 labeling in place of CD18 labeling was
to attempt quantification of both activated myeloid cells inside lesions and non-activated myeloid cells remaining outside lesions. However, in this set of results, we
have only examined Iba1-positive cells within lesions, in parallel to analyses of lesional CD18-positive cells in other parts of the text. Values represent means ± S.D.
Statistically significant differences evaluated by ANOVA and t-test are indicated by *P < 0.05, **P < 0.01, and ***P < 0.001 when values were compared between controls
and NG2 conditional knockout mice at the same time point. Cell and axon numbers are determined in 100,000-μm3 volumes.
(See figure on previous page.)
Fig. 2 Quantification of myelin damage and repair and myeloid cell recruitment from bone marrow. One week after surgery, MBP (green) and
CD18 (blue) expression are shown in control mice injected with PBS (a; Sham-Cont), and in control mice (b; Cont-1W), OPC-NG2ko mice (c; O-cKO-
1W), and My-NG2ko mice injected with lysolecithin (d; M-cKO-1W). To quantify the extent of myelin damage, CD18-associated MBP (cyan) is
subtracted from total MBP to provide a value for axon-associated myelin. e MBP-positive volumes are evaluated in control, OPC-NG2ko mice,
and My-NG2ko mice 1, 2, and 6 weeks after lysolecithin microinjection, respectively. One hundred percent myelination is defined by the level
of MBP labeling in sham-operated control mice. Demyelination is reduced by myeloid-specific, but not by OPC-specific, NG2 ablation. On the
other hand, remyelination is retarded in both lines of NG2-null animals. f Significantly reduced infiltration by CD18-positive immune cells is seen in
My-NG2ko mice compared to control or OPC-NG2ko mice. Wild-type (WT) mice transplanted with EGFP-positive wild-type bone marrow (g) and
germline NG2-null (KO) mice transplanted with germline NG2-null bone marrow (h) were used for lysolecithin injections. Lesions were examined at
1 week post-surgery for co-localization of EGFP (green) and F4/80 (red). The recruitment of F4/80+EGFP+ cells to lesions in WT-to-WT chimeras
is more than fivefold greater than that seen in KO-to-KO transplants (j). The 8:1 ratio of F4/80+EGFP+ to F4/80+EGFP− cells in WT-to-WT
chimeras falls to 1:3 in KO-to-KO chimeras as a result of reduced macrophage recruitment from the circulation (i). Quantification (f) represents
the percentage of MBP-positive volume occupied by CD18 labeling. Values represent means ± S.D. Statistically significant differences evaluated
by ANOVA and t-test are indicated by *P < 0.05; **P < 0.01; *** P < 0.001 when values were compared between controls and cell-type-specific
(e, f) or germline (j) NG2-null mice at the same time point; bP < 0.01; cP < 0.001 indicate statistically significant differences within the same
genotype at 1 and 6 weeks after lysolecithin injection. Scale bars represent 200 μm (a–d) and 50 μm (g, h)
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between these two markers. In control mice (Fig. 6d),
NF-positive axons are almost always seen in close
association with MBP in the central area of the
remyelinating lesion. However, in OPC-NG2ko
(Fig. 6e) and My-NG2ko (Fig. 6f ) mice, numerous
NF-positive axons still lack association with MBP.
These data are quantified in Fig. 7g. These findings
are supported by examination of toluidine-blue-
stained semi-thin sections. Compared to lesions in
control mice (Fig. 6g), lesions in OPC-NG2ko (Fig. 6h)
and My-NG2ko (Fig. 6i) mice contain 50 % fewer
well-myelinated fibers (arrowheads) as well as increased
numbers of axons with thin, irregular myelin sheaths (as-
terisks). These data are also presented in Table 1, row 7.
Additional irregularities in lesional axons in OPC-NG2ko
mice (Fig. 7d–f ) are seen in electron microscopic compar-
isons with lesional axons in control mice (Fig. 7a–c).
Determination of g values (axon diameter/myelinated fiber
diameter) for lesional axons reveals an overall decrease in
myelin thickness (increased g value) in OPC-NG2ko and
My-NG2ko mice (Fig. 7h). The mean g value for control
mice is 0.74, compared to 0.86 and 0.87 in OPC-NG2ko
and My-NG2ko mice, respectively. (See also Table 1, row 8.)
An additional finding from the MBP/NF double label-
ing study is the reduced number of NF-positive axons
present in 6-week lesions in OPC-NG2ko (Fig. 7j) and
My-NG2ko (Fig. 7k) mice compared with control mice
(Fig. 7i). The abundance of axons of all sizes is reduced
by OPC-specific and myeloid-specific ablation of NG2.
These data are quantified in Table 1, row 9.
Discussion
Multiple sclerosis (MS) is a major cause of non-
traumatic neurological disability among young adults in
Fig. 3 Myelin phagocytosis by CD18-expressing myeloid cells. Double immunolabeling for CD18 (green) and MBP (red) was used to quantify myelin
phagocytosis by bone-marrow-derived macrophages in culture (a–h, DAPI in blue). In contrast to myelin phagocytosis by wild-type (WT) macrophages
(a–d), NG2-null (KO) macrophages (e–h) exhibit reduced myelin phagocytosis after 4 h of incubation. Panel (i) quantifies these results over an 8-h time
period (means ± S.D.). Panels (j) and (k) show a similar analysis of CD18/MBP double labeling in vivo at 1-week post-lysolecithin injection. Quantification
is shown for both total MBP pixel density (k) and MBP pixels/CD18+ cell (k). **P < 0.01; ***P < 0.001. Scale bar indicates 100 μm for panels (a–h)
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North America. During the acute phase of MS, damage
to the blood-brain barrier allows infiltration of blood-
derived cells that cause disruption of the myelin sheath
surrounding axons in the central nervous system (CNS)
[29–32]. This damage not only impairs axon ability to
conduct impulses but also eventually leads to loss of the
neurons themselves. Regeneration of myelin is not medi-
ated by surviving oligodendrocytes but instead by new
oligodendrocytes generated by oligodendrocyte progeni-
tors [3, 4, 6]. This process works well in experimental
models of myelin damage and repair but is often much
less effective in complex demyelinating pathologies such
as MS. Possible explanations for the incomplete remyeli-
nation seen in these complex pathologies include the
failure of OPC recruitment into lesions, exhaustion of
the proliferative capacity of OPCs, failure of demyeli-
nated axons to interact with OPCs, and failure of OPCs
to differentiate into mature oligodendrocytes [33–36].
These processes are also impacted by non-neural cell
types that influence key interactions between OPCs and
neurons. Improved treatment of MS requires a more
complete understanding of factors that contribute to
these various phenomena.
Our work with germline NG2-null mice has shown
that genetic ablation of the NG2 proteoglycan negatively
affects both developmental myelination in the early post-
natal cerebellum [14] and remyelination of demyelinated
lesions in the adult spinal cord [15]. Our work has fur-
ther suggested that the involvement of NG2 in demye-
lination and remyelination may be more complex than
its involvement in developmental myelination. This is
due at least partly to the expression of NG2 by three
distinct cell types that contribute in different ways to the
properties of remyelinating lesions. NG2 expression is
seen on OPCs, myeloid cells, and pericytes that are re-
cruited to demyelinated lesions generated in the spinal
cord white matter as a result of lysolecithin microinjec-
tion [15]. Use of Cre-Lox technology has allowed us to
undertake dissection of NG2 roles in two of these cell
populations: OPCs and myeloid cells. Cre-mediated
Fig. 4 OPC abundance in lesions 1 week after lysolecithin microinjection. Larger numbers of PDGFRα (Pα, green)/Olig2-positive (blue) OPCs (arrows) are
seen in lesions in control mice (a, d, g; Cont-1W) than in lesions in OPC-NG2ko (b, e, h; O-cKO-1W) or My-NG2ko mice (c, f, i; M-cKO-1W). Scale bar is 30 μm
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ablation of NG2 in OPC-NG2ko and My-NG2ko mice
has proved to be very efficient. At least 95 % of
PDGFRα-positive/Olig2-positive OPCs are NG2-
negative in OPC-NG2ko mice. NG2 ablation appears to
be somewhat less effective in My-NG2ko mice, with
25 % of CD18-positive cells, 18 % of CD11b-positive
cells, and 12 % of F4/80-positive cells remaining positive
for NG2. This might be a real effect, due to lower effi-
cacy of the LysM promoter compared to the Olig2 pro-
moter [37]. However, it might also be partly artifactual
due to myeloid phagocytosis of proteolytically shed
NG2, contributing to association of NG2 immunofluor-
escence with CD18-positive cells. Regardless, there is a
significant reduction of NG2 expression by myeloid cells
in My-NG2ko mice, and the effect of NG2 loss on mye-
loid cell biology is quite robust.
Since we have previously reported that germline NG2
ablation causes transient, early postnatal deficits in de-
velopmental myelination [14], an important preliminary
aspect of our studies has been establishing that the
status of oligodendrocyte lineage cells and myelination
in adult OPC-NG2ko and My-NG2ko mice does not
differ significantly from that found in control mice. We
suspected that this would be the case, based on the fact
that developmental myelination in germline NG2-null
mice appears to catch up with myelination in wild-type
mice by the end of the third postnatal week [14]. However,
for a more rigorous analysis, we demonstrate here that
numbers of OPCs, total numbers Olig2-positive cells, and
overall volume of myelination (judged by immunolabeling
for MBP) are similar in control, OPC-NG2ko, and My-
NG2ko adult mice. Questions regarding possible effects of
the Olig2-Cre transgene on myelination have been previ-
ously answered by the finding that myelination is normal
in Olig2/Olig2-Cre heterozygotes [38], which is the geno-
type used in our studies.
The extent of initial lysolecithin-induced myelin
damage is not altered by OPC-specific NG2 ablation, indi-
cating the lack of an NG2-dependent effect of OPCs on
demyelination. This is not surprising in light of the
absence of evidence in support of OPC involvement in
demyelination.
In contrast to OPC-NG2ko mice, My-NG2ko mice ex-
hibit deficits in myelin damage. At 1 week after lysolecithin
injection, lesions in My-NG2ko spinal cords are roughly
40 % smaller than lesions in control and OPC-NG2ko
Fig. 5 Proliferation of OPCs in lesions 1 week after lysolecithin microinjection. Larger numbers of proliferating BrdU-positive (green) PDGFRα-positive
(blue, cell surface)/Olig2-positive (cyan, nucleus) OPCs (arrows) are seen in lesions in control mice (a, d; Cont-1W) than in lesions in OPC-NG2ko (b, e;
O-cKO-1W) or My-NG2ko (c, f; M-cKO-1W) mice. The greatly reduced number of total BrdU-positive cells in M-cKO ( c) is due to significantly decreased
numbers of macrophages/microglial cells. Scale bars are 160 μm (a–c) and 24 μm (d–f)
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spinal cords. The most likely cause for this reduced dam-
age in My-NG2ko mice is the large decrease in recruitment
of macrophages that contribute to demyelination. This de-
crease is also seen in bone marrow transplants from
EGFP-positive wild-type and germline NG2-null donors,
establishing that the effect on macrophage recruitment is
independent of the mechanism of NG2 ablation. These
bone marrow transplantation data also support the idea
that the large majority of myeloid cells in lesions in wild-
type mice is recruited from the circulation, since EGFP-
positive myeloid cells outnumber EGFP-negative resident
myeloid cells by an 8:1 ratio. A similar decrease in
macrophage recruitment has been observed in our work
with brain tumors in My-NG2ko mice [28], suggesting that
impaired macrophage infiltration may be a general conse-
quence of NG2 ablation in myeloid cells. The ability of
NG2 to potentiate integrin activation [18, 39, 40] suggests
the possibility that loss of NG2 might diminish the ability
of macrophage integrins to bind to their endothelial
ligands, with subsequent negative effects on macrophage
extravasation into tissues. In support of this concept, we
have used conformationally sensitive integrin antibodies to
show that NG2 knockdown in macrophages diminishes
the activation status of β1 and β2 integrins in the
Fig. 6 Regeneration of myelin. Six weeks after lysolecithin microinjection, fewer APC-positive cells are seen in lesions in OPC-NG2ko (b; O-cKO-6W) and
My-NG2ko (c; M-cKO-6W) mice than in lesions in control (a; Cont-6W) animals. Also, reduced association of MBP-positive myelin (green) with pan-
neurofilament-positive axons (NF, blue, arrows) is detected in the central region of lesions in OPC-NG2ko (e) and My-NG2ko (f) animals compared to
lesions in control mice (d). In semi-thin sections, fewer well-myelinated fibers detected by toluidine blue staining (TB; arrowheads) are seen in lesions of
OPC-NG2ko (h) and My-NG2ko (i) mice than in control (g) animals. Increased examples of poorly myelinated axons with thin, irregular myelin sheaths
(asterisks) are detected in OPC-NG2ko and My-NG2ko mice relative to control animals. Scale bars indicate 20 μm (a–c), 30 μm (d–f), and 10 μm (g–i)
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knockdown cells [41]. α4β1 and αMβ2 interactions with
VCAM1 and ICAM1, respectively, on endothelial cells
are central to leukocyte arrest and subsequent transmi-
gration across the vascular endothelium [42–44]. It
remains for us to demonstrate that NG2 knockdown
also impairs macrophage transmigration of the vascular
endothelium. In light of the importance of macrophage
extravasation in normal immune surveillance and in
Fig. 7 Remyelination and axon survival. Six weeks after lysolecithin microinjection, normally myelinated axons, characterized by pale axoplasm,
neurofilaments, microtubules, mitochondria, and smooth endoplasm reticulum, are more numerous in lesions in control (a–c) than in OPC-NG2ko
(d–f) mice. Panel (a) shows a well-myelinated axon (arrow, magnified in b) and a thinly remyelinated axon (arrowhead, magnified in c). Panel (d)
shows an empty axon-like structure (double arrowhead, magnified in e) and an axon with degenerated axoplasm (asterisk, magnified in f). These
structures are more numerous in OPC-NG2ko mice than in control mice. Quantitative analysis of pan-neurofilament-positive axons lacking
association with MBP (from data represented in Fig. 6d–f) reveals increased numbers of unmyelinated axons in OPC-NG2ko and My-NG2ko mice
(g). h Plotting g values (ratio of axon diameter to myelinated axon diameter) against axon diameter (h) reveals reduced myelin thickness
(increased g value) in lesions in both OPC-NG2ko and My-NG2ko mice. In comparison with lesions in control mice (i), fewer NF-positive axons of
all sizes are seen in lesions in OPC-NG2ko (j) or My-NG2ko (k) animals. Blue, green, and red colors indicate axons with diameters smaller than 1 μm,
between 1 and 2.5 μm, and larger than 2.5 μm, respectively, as determined with image analysis software. Scale bars indicate 2 μm (a, d), 500 nm
(b, c, f), 1 μm (e), and 40 μm (i–k)
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multiple pathologies, understanding the involvement of
NG2 in mechanisms that underlie transendothelial mi-
gration is an important goal.
Compared to control mice, myelin repair is slowed by
the specific loss of NG2 from OPCs, suggesting an
NG2-dependent loss of OPC function in OPC-NG2ko
mice. The effect of NG2 ablation on OPC biology is
initially apparent in the reduced mitotic index seen for
OPCs in OPC-NG2ko mice. This decrease in OPC pro-
liferation results in generation of a smaller than normal
pool of progenitors at 1 week post-injury, leading to
reduced numbers of mature oligodendrocytes at 6 weeks
after injury. These findings in OPC-NG2ko mice are
consistent with our reports of decreased OPC prolifera-
tion during both developmental cerebellar myelination
[14] and spinal cord remyelination [15] in germline NG2-
null mice. In addition, we have previously demonstrated
the importance of NG2 for cell proliferation in several in
vitro [18, 45–47] and in vivo [48–50] models. This suggests
a general role for NG2 in promoting cell proliferation. This
capability of NG2 is based on its ability to enhance both in-
tegrin and growth-factor-mediated signaling mechanisms
that control cell proliferation [18, 45, 46, 51].
In spite of the reduced size of demyelinated lesions in
My-NG2ko mice, myelin repair in these mice is also slow
compared to control lesions. One explanation for this is
suggested by the reduced OPC mitotic index observed in
My-NG2ko mice. OPC proliferation is decreased in My-
NG2ko mice to an even greater extent than in OPC-
NG2ko mice, with correspondingly larger reductions in
both mature oligodendrocytes and interactions of MBP-
positive processes with axons. Reduced proliferation of
OPCs in My-NG2ko mice could be due to the diminished
numbers of macrophages, resulting in decreased produc-
tion of cytokines/chemokines that affect various aspects of
OPC biology [52–55]. However, the fact that My-NG2ko
mice exhibit a larger deficit in OPC proliferation and
abundance than seen in OPC-NG2ko mice indicates that
an additional factor could also be at work. Since macro-
phages have an important role in phagocytosis of myelin
debris [32, 56, 57], reduced macrophage infiltration in
My-NG2ko mice might result in failure to clear myelin
debris, leading to additional inhibition of OPC prolifera-
tion. In fact, our data demonstrate that overall phagocyt-
osis of myelin debris is reduced by 40 % in My-NG2ko
mice. Our in vivo results during the first week after the
demyelination event do not detect impaired phagocytosis
at the level of individual myeloid cells, suggesting that
reduced clearance of myelin debris may be due solely to
reduced macrophage recruitment in My-NG2ko mice.
However, studies performed in vitro demonstrate that
NG2-null macrophages are deficient in short-term
phagocytosis of myelin compared to wild-type macro-
phages. These deficits in clearance of myelin debris
might also contribute to diminished myelin repair, inde-
pendent of changes in OPC proliferation. Additional work
will be required to evaluate the mechanistic basis of NG2-
dependent macrophage/microglia effects on OPC prolifer-
ation, clearance of myelin debris, and myelin repair. It is
also possible that NG2 ablation has other effects on mye-
loid cell function. For example, in our previous study of
lysolecithin-induced demyelination in germline NG2-null
mice, we detected changes in cytokine levels indicative of
a shift in macrophage polarization from a pro-
inflammatory to anti-inflammatory phenotype [15]. It re-
mains to be determined whether such changes in cytokine
profiles can be demonstrated in My-NG2ko mice and
whether these changes can be specifically linked to macro-
phages, as opposed to other cell types in the lesion.
Reduced remyelination in OPC-NG2ko and My-NG2ko
mice is most apparent in specimens double-stained for NF
and MBP to identify changes in interactions between axons
and myelinating oligodendrocytes. At 6 weeks after the
initial demyelination, many axons in the central area of
lesions in OPC-NG2ko and My-NG2ko mice still lack as-
sociation with MBP-positive oligodendrocytes, in contrast
to the extensive MBP association with axons seen in con-
trol mice. These findings at the level of immunostaining
are reinforced by higher power examination of lesions in
semi-thin and ultra-thin sections from control, OPC-
NG2ko, and My-NG2ko mice. Well-myelinated axons
are less abundant in lesions in OPC-NG2ko and My-
NG2ko mice. In addition, determination of g values for
axons in these lesions reveals a statistically significant
decrease in myelin thickness for axons in OPC-NG2ko
and My-NG2ko mice.
It is extremely significant that our comparison of axon
abundance in lesions in control, OPC-NG2ko, and My-
NG2ko mice reveals the neuroprotective effect of OPCs
and/or oligodendrocytes. At 6 weeks post-injury, the
decrease in axon abundance across all axon size classes
in the lesion center of OPC-NG2ko and My-NG2ko
mice is well-correlated with the decreased number of
oligodendrocytes, the diminished association of MBP
with axons, and the reduced myelin thickness in these ani-
mals. This finding reinforces the concept that demyelin-
ation affects not only impulse conduction in axons but,
more importantly, the survival of axons [1, 2, 58]. Prior to
actual myelination, it is also possible that OPC association
with axons has neuroprotective effects [59, 60].
In contrast to our studies with the lysolecithin-mediated
demyelination model, previous use of an EAE model failed
to detect a role for NG2 in demyelination and remyelina-
tion of the spinal cord [16]. Although this EAE study was
able to document the participation of NG2-positive OPCs
and leukocytes during myelin damage and repair, use of
neither germline NG2-null mice nor wild-type mice trans-
planted with NG2-null bone marrow was able to
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demonstrate an effect of NG2 ablation at several levels, in-
cluding disease severity and recovery, extent and repair
of demyelination, and participation of OPCs and mye-
loid cells. Although it is not possible to provide a de-
finitive answer that explains the different outcomes of
the EAE and lysolecithin studies, we would point out
key differences between the two animal models that
may be contributing factors. Differences in the initi-
ation, type, and chronicity of immune responses in the
two models may underlie the differences in experimental
results reported for the lysolecithin [15] and the EAE
model [16]. EAE is an autoimmune-based model that en-
gages both the adaptive and innate immune systems [61],
producing fairly widespread damage to the CNS and result-
ing in a severe pathological phenotype. The lysolecithin
model does not engage the adaptive immune system but
relies on the action of the toxin to open the blood-brain
barrier in a very focal manner, allowing engagement of the
innate immune system [9]. The resulting lysolecithin-
induced damage to myelin is very well-localized to the site
of injection and results in very little pathological phenotype.
An additional feature of the EAE model is the long-lasting
nature of the innate immune response mediated by lym-
phocytes, resulting in frequent secondary attack and dam-
age to areas under repair. While these phenomena are also
characteristic of MS lesions, they inevitably complicate the
detailed analysis of damage and repair in the EAE model.
Thus, while the lysolecithin model could be considered to
be at a disadvantage in terms of the absence of an adaptive
immune component, it nevertheless has the distinct ad-
vantage of allowing exact localization of the site that needs
to be analyzed, along with the ability to follow the some-
what simplified damage and repair processes. It is highly
unlikely that our data would be as robust as they are if our
analyses were made at a site that is peripheral to the pri-
mary site of the damage or if we could not identify
whether lesions were in a damage or repair phase. Al-
though we would not dispute the great utility of the EAE
model in terms of its ability to mimic several key features
of MS, the more random and recurring nature of damage
in this autoimmune model makes it more difficult to
choose optimal sites for detailed analysis. The extensive
use of both types of models (and others) in published
studies of myelin damage and repair illustrates the diffi-
culty in choosing an optimal demyelination model but
also supports the idea that each model has its respective
strengths in terms of providing information relevant to
myelin damage and repair.
In summary, our results demonstrate that NG2 is an
important factor in OPC-dependent regeneration of white
matter following spinal cord demyelination. Cell-type-
specific ablations of NG2 reveal that the proteoglycan func-
tions as both an OPC-intrinsic and OPC-extrinsic factor in
promoting the OPC proliferation that precedes generation
of mature oligodendrocytes and subsequent remyelination.
In light of the key role played by macrophages/microglia in
myelin damage and repair, the ability of NG2 to promote
myeloid cell recruitment is an intriguing topic that merits
further study.
Conclusion
Using a lysolecithin microinjection model of spinal cord de-
myelination, we show that the NG2 proteoglycan is in-
volved in the contributions of both OPCs and myeloid cells
to the processes of myelin damage and repair. Specific abla-
tion of NG2 in OPCs diminishes OPC proliferation, result-
ing in the generation of reduced numbers of mature
oligodendrocytes and decreased remyelination of axons in
lysolecithin-induced lesions. The specific ablation of NG2
in myeloid cells greatly reduces myeloid cell recruitment
following lysolecithin-induced damage. Diminished macro-
phage numbers are responsible for a decrease in initial le-
sion size but also result in reduced lesion repair. This
decreased repair may be due to reduced clearance of myelin
debris in macrophage-deficient lesions but may also stem
from the diminished OPC proliferation that is observed in
the absence of macrophage-derived factors. Deficits in
remyelination in both OPC-NG2ko and My-NG2ko mice
are evident at two levels: (a) quantitative immunolabeling
for MBP and (b) electron microscopic evaluation of myelin
g values and numbers of myelinated axons. An important
aspect of our results is the finding of reduced numbers of
axons in incompletely remyelinated lesions in both OPC-
NG2ko and My-NG2ko mice, emphasizing the importance
of myelin for long-term axon survival.
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receptor alpha; VCAM1: vascular cell adhesion molecule; α4β1: integrin alpha-4/
beta-1; αMβ2: integrin alpha-M/ beta-2.
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